TheKITD816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease-Reference-Cited by-同舟云学术

TheKITD816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease

Published:2014-04-17 Issue:6 Volume:69 Page:810-813
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Hoermann G.¹,Gleixner K. V.²,Dinu G. E.³,Kundi M.⁴,Greiner G.¹,Wimazal F.⁵,Hadzijusufovic E.²⁶⁷,Mitterbauer G.¹,Mannhalter C.¹,Valent P.²⁶,Sperr W. R.²⁶

Affiliation:

1. Department of Laboratory Medicine; Medical University of Vienna; Vienna Austria

2. Division of Hematology & Hemostaseology; Department of Medicine I; Medical University of Vienna; Vienna Austria

3. University of Applied Sciences; Wiener Neustadt Austria

4. Institute of Environmental Health; Medical University of Vienna; Vienna Austria

5. Department of Obstetrics and Gynecology; Medical University of Vienna; Vienna Austria

6. Ludwig Boltzmann Cluster Oncology; Medical University of Vienna; Vienna Austria

7. Department of Companion Animals and Horses; Clinic for Internal Medicine and Infectious Diseases; University of Veterinary Medicine Vienna; Vienna Austria

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Reference15 articles.

1. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis;Longley;Proc Natl Acad Sci USA,1999

2. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder;Nagata;Proc Natl Acad Sci USA,1995

3. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria;Valent;Eur J Clin Invest,2007

4. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis;Gotlib;Blood,2013

5. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay;Kristensen;J Mol Diagn,2011

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Advanced Systemic Mastocytosis: Clinical Challenges;Journal of Blood Medicine;2024-09

2. Unraveling the Rare Entity of KIT D816V-Negative Systemic Mastocytosis;Journal of Hematology;2024-06

3. SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis;Clinical Lymphoma Myeloma and Leukemia;2024-06

4. Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation;British Journal of Haematology;2024-05-04

5. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis;Blood Journal;2023-12-24